WuXi Biologics & Bayer Conclude Takeover Agreement For Pharma Production

WuXi Biologics (“WuXi Bio”) (2269.HK), a company with a leading global open access technology platform for the discovery, development and manufacture of Biologika and Bayer jointly announced an agreement to take over the operation of one of Bayer’s finished pharmaceutical products manufacturing facilities in Leverkusen and purchase of the related equipment in connection with a long-term lease for the building by WuXi Biologics Germany GmbH.The plant is to be operated by WuXi Biologics on the basis of a production contract that is still to be negotiated and will serve as a back-up location for the manufacture of the end product Kovaltry ™, a medicinal product that contains human recombinant coagulation factor VIII. The transaction is expected to close in the coming months, subject to the usual closing conditions. Financial details have not been released.

“We are pleased to sign the transfer agreement with Bayer, who gives us quick access to high-quality pharmaceutical production capacities and capabilities,” said Dr. Chris Chen , CEO of WuXi Biologics. “Our business in the EU, the US and China is This additional pharmaceutical production facility has confirmed our commitment as part of our corporate strategy, ‘Global Dual Sourcing’. WuXi Biologics will continue to expand its global capacities and provide global partners with a robust and high-quality supply chain network for the benefit of patients worldwide .-PR Newswire